[Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Kobayashi
Katsuya
K
Department of Gastroenterology, Faculty of Medicine, University of Tokyo.
Fujishiro
Mitsuhiro
M
Omata
Masao
M
Oka
Masashi
M
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000658:Amoxicillin / Q000008:administration & dosage* / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017291:Clarithromycin / Q000008:administration & dosage* / Q000009:adverse effects; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D016481:Helicobacter Infections; D016480:Helicobacter pylori; D006801:Humans; D064747:Lansoprazole; D008795:Metronidazole / Q000008:administration & dosage / Q000009:adverse effects; D009853:Omeprazole / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D054328:Proton Pump Inhibitors; D013997:Time Factors; D016896:Treatment Outcome
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D064747:Lansoprazole; D008795:Metronidazole; D000658:Amoxicillin; D017291:Clarithromycin; D009853:Omeprazole